GlassScriptPhysician profile
Amanda Nuckols
NPI 1801360086
$1,983.66
in general payments reported to CMS, 2019-2025
26 companies · $87.31 in 2025
The $87.31 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $660 · 2022: $411 · 2023: $538 · 2024: $288 · 2025: $87.31.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $896 · Education: $16.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $896.10 |
| Education | $16.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $263.82 | 2021-2025 | |
| Seagen INC. | $241.50 | 2021-2023 | Tukysa |
| Astrazeneca Pharmaceuticals LP | $210.20 | 2021-2023 | Calquence, Andexxa, Enhertu |
| Amgen INC. | $161.79 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $137.91 | 2021-2023 | |
| Sobi, INC | $126.58 | 2022-2023 | |
| Novo Nordisk INC | $118.48 | 2022 | |
| Glaxosmithkline, LLC. | $112.36 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $93.14 | 2021-2023 | Reblozyl |
| Janssen Pharmaceuticals, INC | $66.06 | 2021 | |
| Daiichi Sankyo INC. | $54.62 | 2023-2025 | Vanflyta, Enhertu |
| Beigene USA, INC. | $49.04 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $48.95 | 2021-2023 | |
| Jazz Pharmaceuticals INC. | $37.94 | 2021-2023 | |
| Janssen Biotech, INC. | $34.97 | 2022-2023 | Erleada |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $33.40 | 2023-2025 | Vyloy |
| Boston Scientific Corporation | $28.00 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $26.67 | 2021 | |
| Incyte Corporation | $23.72 | 2023 | Pemazyre, Monjuvi |
| G1 Therapeutics, INC. | $21.62 | 2023 | Cosela |
| Pharmacyclics LLC, An Abbvie Company | $19.87 | 2023 | Imbruvica |
| Davol INC. | $16.57 | 2022 | |
| Genentech USA, INC. | $15.32 | 2022 | |
| Taiho Oncology, INC. | $14.33 | 2021 | |
| Celgene Corporation | $13.77 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $13.03 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Nuckols listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.